Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Killing the messenger

Nature Reviews Drug Discovery volume 3, pages 823–824 (2004)Cite this article

Public companies mentioned and stock prices as of August 3, 2004

  • AVI BioPharma (AVII $1.90, not rated)

  • Alnylam Pharmaceuticals (ALNY $5.35, not rated)

  • CytRx Laboratories (CYTR $1.10, not rated)

  • Eli Lilly (LLY $63.22, not rated)

  • Genta (GNTA $1.70, Sell)

  • Hybridon, Inc. (HBY $0.46, Buy)

  • Isis Pharamceuticals (ISIS $4.60, not rated)

  • Lorus Therapeutics (LRP $0.51, not rated)

  • NeoPharm (NEOL $6.17, not rated)

  • Sirna Therapeutics (RNAI $2.72, not rated)

AVI BioPharma (AVII $1.90, not rated)

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Proportion of mRNA-targeted agents in each stage of clinical development, by technology.

References

  1. Opalinska, J. B. & Gewirtz, A. M. Nucleic-acid therapeutics: basic principles and recent applications. Nature Rev. Drug Discov. 1, 503–514 (2002).

    Article  CAS  Google Scholar 

  2. Agrawal, S. & Kandimalla, E. R. Antisense therapeutics: is it as simple as complementary base recognition? Mol. Med. Today 6, 72–80 (2000).

    Article  CAS  Google Scholar 

  3. Dorsett, Y. & Tuschl, T. siRNAs: applications in functional genomics and potential as therapeutics. Nature Rev. Drug Discov. 3, 318–329 (2004).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. biotech/therapeutics analyst at Merriman Curhan Ford & Co., 601 Montgomery Street 18th Floor, San Francisco, 94111, California, USA

    Katharine E. Winkler

Authors
  1. Katharine E. Winkler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winkler, K. Killing the messenger. Nat Rev Drug Discov 3, 823–824 (2004). https://doi.org/10.1038/nrd1527

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1527

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing